CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 29 enrolled
Drug / intervention
Calcium stable isotopeother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01304407
NCT01304407N/ACompleted
CompareCT.gov

Evaluation of Calcium Absorption in Patients With Rothmund-Thomson Syndrome

Baylor College of Medicine·interventional·Posted Feb 25, 2011·Updated Jul 23, 2020

In Brief

A clinical study evaluating Calcium stable isotope for Rothmund-Thomson Syndrome. Completed, enrolled 29 participants across 1 site.

Detailed Summary

Osteosarcoma is the most common malignant bone tumor in children and adolescents. Because cure rates for osteosarcoma have remained stagnant for the past several decades despite numerous trials of chemotherapy agents, novel therapies based on the understanding of the molecular pathogenesis of osteosarcoma are needed. Rothmund-Thomson Syndrome (RTS) is a genetic disorder affecting many parts of the body and resulting in major skeletal abnormalities. This disease also has the propensity to increase the risk of developing cancer, particularly osteosarcoma. Two-thirds of RTS patients have a high risk of developing osteosarcoma. Therefore, it is important to understand the impact of RTS on the skeletal phenotype (as measured by bone density) in order to develop effective therapies to battle osteosarcoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRothmund-Thomson Syndrome
CountriesUnited States
CollaboratorsUnited States Department of Agriculture (USDA), National Institutes of Health (NIH), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Gillson-Longenbaugh Foundation

Timeline

N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 25, 2011
Enrollment StartMar 1, 2011
Primary CompletionOct 1, 2015
Study CompletionFeb 1, 2017
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 15.4 years ago

Interventions

Calcium stable isotopeother

Subjects consume breakfast and 180 ml of calcium-fortified orange juice to which 20 mg of 46Ca stable isotope was added. Immediately after breakfast, subjects receive 5 mg of 42Ca intravenously.